TNFRSF10A and Miyoshi myopathy: In line with previous observations that bortezomib upregulates the expression of death receptors TRAIL-R1 and-R2[35–37], we observed that bortezomib treatment significantly upregulated cell surface expression of TRAIL-R1 in MM cells that do not carry the del(8)(p21), making them vulnerable to TRAIL mediated apoptosis.